<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30206184</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>12</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1557-3125</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                        <Day>11</Day>                    </PubDate>                </JournalIssue>                <Title>Molecular cancer research : MCR</Title>                <ISOAbbreviation>Mol. Cancer Res.</ISOAbbreviation>            </Journal>            <ArticleTitle>SOX9/FXYD3/Src axis is critical for ER+ breast cancer stem cell function.</ArticleTitle>            <ELocationID EIdType="pii" ValidYN="Y">molcanres.0610.2018</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1158/1541-7786.MCR-18-0610</ELocationID>            <Abstract>                <AbstractText>The presence of cancer stem cells (CSCs) which possess the ability of self-renewal and cancer-initiation is correlated with poor prognosis and drug resistance of breast cancer patients. But the molecular regulatory networks for maintenance of CSC function still remain unclear. Here we identified an estrogen inducible gene FXYD3, whose expression is significantly up-regulated in ER+ breast CSCs, is a critical player for regulating ER+ breast CSCs function. FXYD3 amplification is crucial in mediating tamoxifen-resistance in ER+ breast cancer cells. Interestingly, we also find that stem cell related transcription factor SOX9 directly promotes FXYD3 expression, and FXYD3 is indispensable for SOX9 nucleus localization, thus forming a positive regulatory feedback loop for FXYD3 amplification and function. In terms of mechanism, FXYD3 interacts with Src and ERα to form an activated complex and triggers Src to transduce non-genomic estrogen signaling for facilitating ER+ breast cancer stem cells. Collectively, these results establish a critical role for SOX9/FXYD3/Src axis in boosting non-genomic estrogen signaling and SOX9 nucleus entry, which is required for maintenance of ER+ breast cancer stem cells and endocrine-resistance. Targeting FXYD3-mediated pathway might be a promising therapeutic strategy for hormone-therapy refractory ER+ breast cancer.</AbstractText>                <AbstractText Label="IMPLICATIONS" NlmCategory="CONCLUSIONS">SOX9/FXYD3/Src axis is critical for promoting cancer stem cell function and tamoxifen-resistance in ER+ breast cancer.</AbstractText>                <CopyrightInformation>Copyright ©2018, American Association for Cancer Research.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Xue</LastName>                    <ForeName>Yue</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Immunology, Zhejiang University.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lai</LastName>                    <ForeName>Lihua</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Immunology, Zhejiang University.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lian</LastName>                    <ForeName>Wenwen</ForeName>                    <Initials>W</Initials>                    <AffiliationInfo>                        <Affiliation>Immunology, Zhejiang University.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tu</LastName>                    <ForeName>Xintao</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Immunology, Zhejiang University.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhou</LastName>                    <ForeName>Jiaojiao</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>The Second Affiliated Hospital, Zhejiang University.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Dong</LastName>                    <ForeName>Ping</ForeName>                    <Initials>P</Initials>                    <Identifier Source="ORCID">https://orcid.org/0000-0002-6640-6607</Identifier>                    <AffiliationInfo>                        <Affiliation>Institute of Neuroscience, School of Medicine, Zhejiang University.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Su</LastName>                    <ForeName>Dan</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Pathology Department, Zhejiang Cancer Hospital, Zhejiang, China; Key Laboratory of Diagnosis and Treatment Technology on Thoracic Oncology of Zhejiang Province; Cancer Research Institute, Zhejiang Cancer Hospital.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Xiaojia</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Breast Cancer, Zhejiang Cancer Hospital.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Cao</LastName>                    <ForeName>Xuetao</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>National Key Laboratory of Medical Immunology &amp; Institute of Immunology, Second Military Medical University.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chen</LastName>                    <ForeName>Yiding</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>oncology, 2nd Affiliated Hospital, Zhejiang University School of Medicine.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Qingqing</ForeName>                    <Initials>Q</Initials>                    <AffiliationInfo>                        <Affiliation>Immunology, Zhejiang University wqq@zju.edu.cn.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>11</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Mol Cancer Res</MedlineTA>            <NlmUniqueID>101150042</NlmUniqueID>            <ISSNLinking>1541-7786</ISSNLinking>        </MedlineJournalInfo>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>30</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>06</Month>                <Day>09</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>08</Month>                <Day>01</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30206184</ArticleId>            <ArticleId IdType="pii">1541-7786.MCR-18-0610</ArticleId>            <ArticleId IdType="doi">10.1158/1541-7786.MCR-18-0610</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>